Vera Therapeutics, Inc. VERA
We take great care to ensure that the data presented and summarized in this overview for Vera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VERA
View all-
Avoro Capital Advisors LLC New York, NY5.27MShares$221 Million2.74% of portfolio
-
Black Rock Inc. New York, NY3.32MShares$139 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.17MShares$133 Million11.79% of portfolio
-
Abingworth LLP London, X02.96MShares$124 Million19.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$117 Million7.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.39MShares$100 Million0.01% of portfolio
-
State Street Corp Boston, MA2.35MShares$98.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$90.1 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY1.82MShares$76.5 Million5.9% of portfolio
-
Morgan Stanley New York, NY1.54MShares$64.5 Million0.01% of portfolio
Latest Institutional Activity in VERA
Top Purchases
Top Sells
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Insider Transactions at VERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
SELL
Open market or private sale
|
Direct |
20,651
-15.41%
|
$867,342
$42.63 P/Share
|
|
May 16
2024
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
BUY
Exercise of conversion of derivative security
|
Direct |
20,651
+12.6%
|
$144,557
$7.87 P/Share
|
|
May 15
2024
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
SELL
Open market or private sale
|
Direct |
10,186
-8.54%
|
$427,812
$42.42 P/Share
|
|
May 15
2024
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
BUY
Exercise of conversion of derivative security
|
Direct |
8,221
+11.81%
|
$24,663
$3.94 P/Share
|
|
Apr 10
2024
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
SELL
Open market or private sale
|
Direct |
5,714
-9.7%
|
$228,560
$40.0 P/Share
|
|
Apr 03
2024
|
Sean Grant CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Indirect |
18,649
-47.42%
|
$727,311
$39.16 P/Share
|
|
Apr 03
2024
|
Sean Grant CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
99,828
-19.27%
|
$3,893,292
$39.02 P/Share
|
|
Apr 03
2024
|
Sean Grant CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
99,828
+37.53%
|
$1,397,592
$14.87 P/Share
|
|
Mar 25
2024
|
Maha Katabi |
SELL
Open market or private sale
|
Indirect |
340,000
-10.85%
|
$13,600,000
$40.5 P/Share
|
|
Mar 22
2024
|
Maha Katabi |
SELL
Open market or private sale
|
Indirect |
413,450
-11.65%
|
$16,538,000
$40.51 P/Share
|
|
Mar 21
2024
|
Maha Katabi |
SELL
Open market or private sale
|
Indirect |
81,009
-0.56%
|
$3,564,396
$44.68 P/Share
|
|
Jan 30
2024
|
Maha Katabi |
BUY
Open market or private purchase
|
Indirect |
161,290
+4.26%
|
$4,999,990
$31.0 P/Share
|
|
Jan 16
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
78,750
+19.0%
|
-
|
|
Jan 16
2024
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
BUY
Grant, award, or other acquisition
|
Direct |
21,875
+27.71%
|
-
|
|
Jan 16
2024
|
Sean Grant CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+25.02%
|
-
|
|
Jan 10
2024
|
Commodore Capital LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,050,000
-19.27%
|
$18,900,000
$18.0 P/Share
|
|
Dec 29
2023
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,516
+2.51%
|
$27,032
$2.61 P/Share
|
|
Dec 20
2023
|
Sean Grant CHIEF FINANCIAL OFFICER |
SELL
Bona fide gift
|
Indirect |
636
-3.41%
|
-
|
|
Aug 21
2023
|
Celia Lin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,490
-11.92%
|
$23,840
$16.65 P/Share
|
|
Aug 21
2023
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
5,210
-2.1%
|
$83,360
$16.66 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 615K shares |
|---|---|
| Grant, award, or other acquisition | 127K shares |
| Exercise of conversion of derivative security | 152K shares |
| Bona fide gift | 1.62K shares |
| Open market or private sale | 2.05M shares |
|---|---|
| Bona fide gift | 2.26K shares |